Eli Lilly Acquires ATAI for $6.75 Per Share, Stock Surges 33% in Pre-Market Trade on July 16

According to Eli Lilly, on July 16, the pharma giant announced it will acquire ATAI at $6.75 per share in cash, with additional milestone payments tied to two lead depression therapies bringing total potential value to $9.25 per share. Based on ATAI's Wednesday close of $5.36, the deal represents a 72.6% premium. ATAI stock jumped over 33% in pre-market trade, while Compass Pathways, a former major ATAI shareholder with a 4.96% stake as of February 2026, gained 7%. The deal is expected to close in Q3, pending shareholder and regulatory approval.
Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.
Comment
0/400
No comments